Literature DB >> 21165213

Kasabach-merritt syndrome arising from tufted angioma successfully treated with systemic corticosteroid.

Taegyun Kim1, Mi Ryung Roh, Soohyun Cho, Kee Yang Chung.   

Abstract

We report a case of Kasabach-Merritt syndrome arising from a tufted angioma successfully treated with systemic corticosteroid. A 2-month-old male infant presented with a palm-sized, erythematous induration on his left pubis. The lesion was diagnosed as tufted angioma histopathologically. After 1 month, the lesion suddenly expanded to the abdomen and scrotum. Initial laboratory tests were consistent with consumptive coagulopathy. He was diagnosed with Kasabach-Merritt syndrome and treated with intravenous dexamethasone at 0.32 mg/kg/day (equivalent to prednisolone 2.0 mg/kg/day). Two days after initiating the treatment, his platelet counts recovered and the lesion ceased to expand. Steroid therapy was converted to oral prednisolone and the dosage was subsequently tapered, and the lesion gradually involuted with no signs of recurrence for a year.

Entities:  

Keywords:  Kasabach-Merritt syndrome; Systemic corticosteroid; Tufted angioma

Year:  2010        PMID: 21165213      PMCID: PMC2991720          DOI: 10.5021/ad.2010.22.4.426

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  17 in total

Review 1.  Kasabach-Merritt syndrome: pathogenesis and management.

Authors:  G W Hall
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

Review 2.  Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience.

Authors:  Vilmarie Rodriguez; Adrianna Lee; Patricia M Witman; Peter A Anderson
Journal:  J Pediatr Hematol Oncol       Date:  2009-07       Impact factor: 1.289

3.  Disseminated intravascular coagulation after excision of giant hemangioma.

Authors:  J Z Jona; H C Kwaan; M Bjelan; J G Raffensperger
Journal:  Am J Surg       Date:  1974-05       Impact factor: 2.565

4.  Hemangioma and thrombocytopenia.

Authors:  A G Martins
Journal:  J Pediatr Surg       Date:  1970-12       Impact factor: 2.545

5.  Management of alarming hemangiomas in infancy: a review of 25 cases.

Authors:  O Enjolras; M C Riche; J J Merland; J P Escande
Journal:  Pediatrics       Date:  1990-04       Impact factor: 7.124

6.  Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome.

Authors:  H Y Shin; K H Ryu; H S Ahn
Journal:  Pediatr Int       Date:  2000-12       Impact factor: 1.524

7.  High-dose oral methylprednisolone therapy in childhood hemangiomas.

Authors:  K M Uysal; N Olgun; A Erbay; F Sarialioğlu
Journal:  Pediatr Hematol Oncol       Date:  2001 Jul-Aug       Impact factor: 1.969

8.  Case report: Kasabach-Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha.

Authors:  S Hesselmann; O Micke; T Marquardt; S Baas; J H Bramswig; E Harms; N Willich
Journal:  Br J Radiol       Date:  2002-02       Impact factor: 3.039

9.  Kasabach-Merritt syndrome in infants.

Authors:  N B Esterly
Journal:  J Am Acad Dermatol       Date:  1983-04       Impact factor: 11.527

10.  Treatment of hemangiomas of infants with high doses of prednisone.

Authors:  N Sadan; B Wolach
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

View more
  11 in total

1.  Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery.

Authors:  Run-song Jiang; Rong Hu
Journal:  Int J Clin Oncol       Date:  2011-09-28       Impact factor: 3.402

2.  Multimodal treatment of Kasabach-Merritt syndrome arising from tufted angioma: A case report.

Authors:  Run-Song Jiang; Zheng-Yan Zhao
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

3.  Kasabach-Merritt syndrome combined with hypercalcemia: A case report.

Authors:  Runying Zou; Fang Peng; Tian Yu; Saizhen Zeng; Yalan You; Keke Chen; Hui Zou; Xin Tian; Chengguang Zhu; Xiangling He
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

4.  Comprehensive Therapy for Infant Vascular Tumor Associated With Kasabach-Merritt Phenomenon-Single-Center Primary Experience.

Authors:  Xiaoting Sun; Miao Xu; Kaiyang Lv; Xiaorong Ma; Liming Wu; Tianxiang Ouyang
Journal:  Front Pediatr       Date:  2022-06-22       Impact factor: 3.569

Review 5.  Standards of care for Kasabach-Merritt phenomenon in China.

Authors:  Wei Yao; Ke-Lei Li; Zhong-Ping Qin; Kai Li; Jia-Wei Zheng; Xin-Dong Fan; Lin Ma; De-Kai Zhou; Xue-Jian Liu; Li Wei; Li Li; Mao-Zhong Tai; Jin-Hu Wang; Yi Ji; Lin Zhou; Hai-Jin Huang; Xiao-Yun Gao; Zhi-Jian Huang; Song Gu; He-Ying Yang
Journal:  World J Pediatr       Date:  2020-08-26       Impact factor: 2.764

6.  Intractable tufted angioma associated with kasabach-merritt syndrome.

Authors:  Jae Woo Choi; Jung Im Na; Jong Soo Hong; Soon Hyo Kwon; Sang Young Byun; Kwang Hyun Cho; Sang Woong Youn; Hyung Soo Choi; Kyoung-Duk Park; Kyoung Chan Park
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

7.  Clinical analysis of Kasabach-Merritt syndrome in 17 neonates.

Authors:  Ping Wang; Wei Zhou; Li Tao; Ning Zhao; Xiao-Wen Chen
Journal:  BMC Pediatr       Date:  2014-06-11       Impact factor: 2.125

8.  Tufted angioma in children: report of two cases and a review of the literature.

Authors:  Alessandra Dutra da Silva; Grasieli de Oliveira Ramos; Rita Fabiane Teixeira Gomes; Marco Antônio Trevizani Martins; Marcelo Lazzaron Lamers; Manoel Santa'Ana Filho; Pantelis Varvaki Rados; Laura de Campos Hildebrand; Fernanda Visioli
Journal:  Case Rep Dent       Date:  2014-11-04

9.  Long-term outcomes of low-dose radiotherapy in Kasabach-Merritt syndrome.

Authors:  Dowook Kim; Jung Yoon Choi; Kyung Taek Hong; Hyoung Jin Kang; Il Han Kim; Joo Ho Lee
Journal:  Radiat Oncol J       Date:  2022-03-22

10.  Tufted angioma (Angioblastoma) of eyelid in adults-report of two cases.

Authors:  Ruchi Mittal; Devjyoti Tripathy
Journal:  Diagn Pathol       Date:  2013-09-17       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.